Mirum Pharmaceuticals Announces Enrollment Completion in Phase 2b EMBARK Biliary Atresia StudyBusiness Wire • 05/11/23
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/04/23
Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdateBusiness Wire • 05/04/23
Mirum Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023Business Wire • 04/27/23
Mirum Pharmaceuticals Prices Upsized $275.0 Million Convertible Senior Notes OfferingBusiness Wire • 04/13/23
Mirum Pharmaceuticals Announces Preliminary Unaudited First Quarter 2023 Financial ResultsBusiness Wire • 04/12/23
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business UpdateBusiness Wire • 03/08/23
Why Mirum Pharmaceuticals (MIRM) Might Surprise This Earnings SeasonZacks Investment Research • 03/02/23
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 03/01/23
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call on March 8, 2023Business Wire • 03/01/23
Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic CholestasisBusiness Wire • 02/14/23
Mirum Pharmaceuticals to Participate in SVB Securities Global Biopharma ConferenceBusiness Wire • 02/09/23
Mirum Pharmaceuticals Announces Preliminary Unaudited LIVMARLI 2022 Net Revenue and Provides Corporate UpdatesBusiness Wire • 01/09/23
Mirum Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023Business Wire • 01/03/23
Mirum Pharmaceuticals' LIVMARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and OlderBusiness Wire • 12/13/22